Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Follow the links below to read about each product:
Camzyos (Bristol Myers Squibb)
Enhertu (Daiichi Sankyo, AstraZeneca)
Rebyota (Ferring Pharmaceuticals)
Tzield (Provention Bio, a Sanofi company)
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
